Bertis specializes in proteomics-based molecular diagnostics, utilizing advanced mass spectrometry techniques to identify protein biomarkers for early cancer detection. Their flagship product, MASTOCHECK, is the first commercial blood test for early breast cancer diagnosis, enabling detection of stages 0 to 2, which is critical for improving patient outcomes.
Funding
$13.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for early cancer detection often lack the sensitivity and specificity needed to identify the disease in its nascent stages, leading to delayed diagnosis and reduced treatment effectiveness. Traditional screening methods may also be invasive or unsuitable for certain patient populations, such as younger women at risk for breast cancer.
Solution
Bertis specializes in proteomics-based molecular diagnostics, employing advanced mass spectrometry to identify protein biomarkers for early cancer detection. Their flagship product, MASTOCHECK, is a blood test designed for the early diagnosis of breast cancer, capable of detecting stages 0 to 2. Bertis leverages its ProteoID technology framework to unravel the proteome, enabling the development of precision medicine solutions. The company's technology allows for the simultaneous and precise quantification of multiple protein biomarkers in blood, improving the accuracy of early diagnosis. Bertis is also developing early diagnosis tests for pancreatic and ovarian cancer.
Target Audience
The primary target audience includes healthcare providers, hospitals, and health screening centers seeking advanced diagnostic tools for early cancer detection, as well as biotech and pharmaceutical companies involved in drug discovery and development.
Features
- MASTOCHECK: A proteomics-based blood test for early breast cancer diagnosis (stages 0-2)
- ProteoID: Core technology framework for proteomics analysis
- PASS (Pan-omics Analysis Service & Solution): Customized proteomics analysis solutions for biomarker discovery, validation, drug R&D, and production
- PepQuant Library: A library of peptides for quantitative proteomics
- DeepMRM: A targeted proteomics method for sensitive and accurate quantification
- SAN (Spectrum is All you Need) model: Uses large language models (LLM) to analyze protein distribution data
- Single-cell proteomics analysis: Qualitative and quantitative analysis of proteins at the single-cell level using next-generation mass spectrometry